Yeong-Jian Jan Wu

Yeong-Jian Jan Wu

Auto-generated profile, based on publicly available information

Yeong-Jian Jan Wu

Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital , Taipei

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 March 2022 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
RKRangi Kandane-Rathnayake
Rangi Kandane-Rathnayake
WLWorawit Louthrenoo
Worawit Louthrenoo
AHAlberta Hoi
Alberta Hoi
SLShue-Fen Luo
Shue-Fen Luo
YWYeong-Jian J. Wu
Yeong-Jian J. Wu
FCFor the Asia-Pacific Lupus Collaboration
For the Asia-Pacific Lupus Collaboration
Background: The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. Methods: Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K ≥10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). Results: A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], p<0.001) and HDAS-ever (adjusted hazard ratio (HR) [95% CI] = 5.45 [2.75, 10.8], p<0.001) patients. Conclusion: Failure to achieve LLDAS, high average disease activity, and episodes of HDAS were prevalent in SLE and were significantly associated with poor outcomes including organ damage, glucocorticoid exposure, poor quality of life, and mortality.


19 May 2023 in Rheumatology
Verified
Journal Article
Open access
PDF file
AYAi Li Yeo
Ai Li Yeo
RKRangi Kandane-Rathnayake
Rangi Kandane-Rathnayake
RKRachel Koelmeyer
Rachel Koelmeyer
VGVera Golder
Vera Golder
WLWorawit Louthrenoo
Worawit Louthrenoo
FCfor the Asia Pacific Lupus Collaboration
for the Asia Pacific Lupus Collaboration
Disease activity monitoring in SLE includes serial measurement of anti-double stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive, the utility of repeated measurement is unclear. We investigated the usefulness of serial anti-dsDNA testing in predicting flare in SLE patients who are persistently anti-dsDNA positive. Data were analysed from patients in a multinational longitudinal cohort with known anti-dsDNA results from 2013 to 2021. Patients were categorized based on their anti-dsDNA results as persistently negative, fluctuating or persistently positive. Cox regression models were used to examine longitudinal associations of anti-dsDNA results with flare. Data from 37 582 visits of 3484 patients were analysed. Of the patients 1029 (29.5%) had persistently positive anti-dsDNA and 1195 (34.3%) had fluctuating results. Anti-dsDNA expressed as a ratio to the normal cut-off was associated with the risk of subsequent flare, including in the persistently positive cohort (adjusted hazard ratio [HR] 1.56; 95% CI: 1.30, 1.87; P < 0.001) and fluctuating cohort (adjusted HR 1.46; 95% CI: 1.28, 1.66), both for a ratio >3. Both increases and decreases in anti-dsDNA more than 2-fold compared with the previous visit were associated with increased risk of flare in the fluctuating cohort (adjusted HR 1.33; 95% CI: 1.08, 1.65; P = 0.008) and the persistently positive cohort (adjusted HR 1.36; 95% CI: 1.08, 1.71; P = 0.009). Absolute value and change in anti-dsDNA titres predict flares, including in persistently anti-dsDNA positive patients. This indicates that repeat monitoring of dsDNA has value in routine testing.

1 July 2021 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
RKRangi Kandane-Rathnayake
Rangi Kandane-Rathnayake
WLWorawit Louthrenoo
Worawit Louthrenoo
SLShue‐Fen Luo
Shue‐Fen Luo
YWYeong‐Jian J. Wu
Yeong‐Jian J. Wu
Yi-Ming ChenYi-Ming Chen
Yi-Ming Chen
FCfor the Asia‐Pacific Lupus Collaboration
for the Asia‐Pacific Lupus Collaboration

15 March 2024 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
VGVera Golder
Vera Golder
RKRangi Kandane-Rathnayake
Rangi Kandane-Rathnayake
WLWorawit Louthrenoo
Worawit Louthrenoo
Yi-Ming ChenYi-Ming Chen
Yi-Ming Chen
JCJiacai Cho
Jiacai Cho
FCFor the Asia-Pacific Lupus Collaboration
For the Asia-Pacific Lupus Collaboration
Objective: To assess whether Lupus Low Disease Activity State (LLDAS) attainment is associated with favorable outcomes in patients with recent onset systemic lupus erythematosus (SLE).Methods: Data from a 13-country longitudinal SLE cohort were collected prospectively between 2013 and 2020. An inception cohort was defined based on disease duration < 1 year at enrollment. Patient characteristics between inception and noninception cohorts were compared. Survival analyses were performed to examine the association between LLDAS attainment and damage accrual and flare.Results: Of the total 4106 patients, 680 (16.6%) were recruited within 1 year of SLE diagnosis (inception cohort). Compared to the noninception cohort, inception cohort patients were significantly younger, had higher disease activity, and used more glucocorticoids, but had less organ damage at enrollment. Significantly fewer inception cohort patients were in LLDAS at enrollment than the noninception cohort (29.6% vs 52.3%,P< 0.001), but three-quarters of both groups achieved LLDAS at least once during follow-up. Limiting analysis only to patients not in LLDAS at enrollment, inception cohort patients were 60% more likely to attain LLDAS (hazard ratio 1.37, 95% CI 1.16-1.61,P< 0.001) than noninception cohort patients and attained LLDAS significantly faster. LLDAS attainment was significantly protective against flare in both the inception and noninception cohorts. A total of 88 (13.6%) inception cohort patients accrued organ damage during a median 2.2 years of follow-up.Conclusion: LLDAS attainment is protective from flare in recent onset SLE. Significant protection from damage accrual was not observed because of low rates of damage accrual in the first years after SLE diagnosis. (ClinicalTrials.gov:NCT03138941)